Gallium bone graft glass kills cancer cells and blocks infection

Researchers have developed a gallium-doped bioactive glass that selectively destroys osteosarcoma cells, blocks bacterial growth and supports bone regeneration. The material could help reduce recurrence, infection and implant failure after limb-salvage surgery for primary bone cancer.

Why it matters: - Primary bone tumors such as osteosarcoma have had stagnant survival rates for decades. - Surgery can leave residual cancer near vital structures, which raises the risk of local recurrence and sometimes amputation. - Bone loss and infection after tumor surgery can also lead to implant failure.

What happened: - An international team led by the Royal Orthopaedic Hospital NHS Foundation Trust, Aston University and the Brazilian Aeronautics Institute of Technology developed a gallium-doped bioactive glass for bone grafting. - The material combines gallium oxide with the traditional Bioglass 45S5 matrix. - The graft is designed to kill leftover cancer cells, prevent bacterial colonization and help regenerate missing bone tissue. - The study was published under DOI 10.1016/j.engreg.2026.05.001.

The details: - The biomaterial acts as a localized drug delivery system at the surgical site. - The glass releases calcium, phosphate and silicon ions that support new bone growth. - High-throughput RNA sequencing showed that osteosarcoma cells absorb four to eight times more gallium than healthy cells because they overexpress transferrin receptors. - Inside cancer cells, gallium mimics iron but cannot take part in essential redox reactions. - That mismatch triggers iron depletion, oxidative stress and cell death through apoptotic and ferroptotic pathways. - Healthy bone cells handle the temporary stress through natural antioxidant mechanisms and recover within days. - The optimal 5% gallium glass formulation completely inhibited Pseudomonas aeruginosa, a gram-negative hospital-acquired pathogen.

Between the lines: - The approach aims to solve three problems from one surgery: residual cancer, infection and poor bone repair. - A treatment that stays local could reduce the need for broader systemic therapy and lower damage to healthy tissue. - The selective uptake of gallium by cancer cells is the key scientific advantage, because it targets malignant tissue more aggressively than normal bone.

What's next: - The work points toward future grafts for limb-salvage surgery that combine therapy, infection prevention and reconstruction in one implant. - Further development will likely focus on translating the material from laboratory results into clinical use. - The research was supported by the Bone Cancer Research Trust, Royal Orthopaedic Hospital Charity, Orthopaedic Research UK, RAEng/Leverhulme Trust, the Paediatric Cancer Research programme at UEA, CNPq and FAPESP.

The bottom line: - The gallium-doped glass is designed to do what current bone cancer surgery often cannot: destroy residual tumor cells, resist infection and rebuild bone at the same time.